Abiopharma

🔍 Repass Wolfe (Executive)

Company: Fold Holdings, Inc. (FLD)

Report Date: 2026-03-19

Detailed Transactions and Holdings:

• Acquired 695 shares of Common Stock (Direct)
  Date: 2026-03-19 | Code: M | equity_swap_involved: false | shares_owned_after: 242,949.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 176 shares of Common Stock at $1.246 per share (Direct)
  Date: 2026-03-20 | Code: S | equity_swap_involved: false | shares_owned_after: 242,773.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 695 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-19 | Code: M | equity_swap_involved: false | shares_owned_after: 1,390.00 | transaction_form_type: 4 | Footnotes: F3, F5, F4, F4

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: The sale reported on this Form 4 represents shares sold by Mr. Repass to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by Mr. Repass.
• F3: Not applicable.
• F4: The restricted stock units vest as to one-fourth of the underlying shares beginning on May 19, 2023 and thereafter in 48 equal monthly installments, subject to Mr. Repass' continued service through the applicable vesting date and a liquidity event vesting condition. The liquidity event vesting condition was deemed met upon the merger of Legacy Fold, Issuer and FTAC EMLD Merger Sub Inc. on February 14, 2025 (the "Merger").
• F5: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of July 24, 2024 (the "Merger Agreement"), by and among the Issuer (formerly FTAC Emerald Acquisition Corp.), FTAC EMLD Merger Sub Inc. and Fold, Inc. ("Legacy Fold"), pursuant to which each outstanding Legacy Fold RSU Award was automatically converted into an award of restricted stock units covering a number of shares of the Issuer's Common Stock based on the exchange ratio described in the Issuer's Registration Statement on Form S-4, as amended (Reg. No. 333-282520).
• REMARKS: Exhibit 24 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24 to the Form 4 filed by Mr. Repass on February 20, 2026).